EFTA01933592

To: Jeffrey epstein [email protected] epstein (jeeyacation©gmail.com)]; [email protected][[email protected]] From: Boris Nikolic Sent: Wed 2/12/2014 7:19:26 PM Subject: another reason Just heard about another reason for a delay — in a draft of PPM we wrote We are in the process of entering into an agreement with Illumina, the leading DNA sequencing company globally that would provide us unique access to sequencing application start-ups that join their incubator program. Today it is finalized - fittp://www.nasdaq.com/press-release/illumina-launches-the-illumina- accelerator-program-worlds-first-genomics-incubator-20140212-00112 This is a great news as this will feed a lot of our pipeline. Illumina is now a world leader in sequencing — so anything that has to do with sequencing there is no better partner. There are few other similar deals in negotiations. This will secure a unique access and scale that other fund can't achieve easily. For some LPs this be significant. B EFTA_R1_00386878 EFTA01933592